It is trading at $0.43 just a bit higher than $0.39, the 50 day moving average and which is just over the 200 day moving average of $0.42. The 50 day moving average was up $0.04 or +9.4615% whereas the 200 day moving average was up $0.00 or +0.4984%. 9,842 shares changed hands in the last trading session. Overall, volume was down 96.15% under the stocks normal daily volume.
Investors are a little more bearish on shares of the company recently as indicated by the increase in short interest. The company saw a rise in short interest of 3.71% between September 15, 2017 and September 29, 2017. Short interest increased 89,435 over that period. Days to cover increased from 5.0 to 11.0 and the percentage of shorted shares is 0.03% as of September 29.
These funds have shifted positions in (BPTH). Sabby Management, LLC grew its stake by buying 503,488 shares an increase of 73.2% from 03/31/2017 to 06/30/2017. Sabby Management, LLC currently owns 1,190,886 shares worth $462,000. The value of the position overall is down by 18.8%. Hightower Advisors, LLC expanded its ownership by buying 4,000 shares an increase of 0.3% in the quarter. Hightower Advisors, LLC now controls 1,267,070 shares with a value of $492,000. The total value of its holdings decreased 52.8%.
Ubs Group Ag divested its holdings by selling 1,417 shares a decrease of 59.7%. Ubs Group Ag controls 956 shares valued at $0. The value of the position overall is down by 100.0%. As of quarter end Meeder Asset Management Inc had bought a total of 2,829 shares growing its holdings by 75.2%. The value of the investment in (BPTH) went from $1,000 to $2,000 increasing 100.0% quarter over quarter.
In the latest earnings report the EPS was $-0.07 and is expected to be $-0.08 for the current year with 100,056,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.02 with next year’s EPS anticipated to be $-0.11.
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Business’s drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately two antisense drug candidates in development to treat a total of over five different disease indications..